Datavault AI Awards $10M Exclusive License to Scilex for Biotech Asset Tokenization
Datavault AI Inc. has announced the signing of a $10 million worldwide exclusive license agreement with Scilex Holding Company for the tokenization and monetization of real-world assets in the biotech and biopharma sector. Under the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. In addition, Datavault AI is eligible to receive up to $2.55 billion in sales milestone payments upon Scilex achieving certain sales targets. The agreement grants Scilex the right to use Datavault AI's proprietary technology for creating and operating a Biotech Exchange platform focused on secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostics, therapeutics, genetic information, and drug data.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Datavault Ai Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568504-en) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.